Radioactive drug takes on brain cancer in early trial

NCT ID NCT05450744

Ongoing Disease control Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-phase trial is testing a radioactive drug called 131I-TLX101, given alongside standard care, for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study involves 12 participants and aims to find the safest dose and check for side effects. It is not yet known if the drug helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 131I-TLX101 (a radioactive drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for glioblastoma, a tough brain cancer.
What could go wrong: This is a very early phase 1 trial with only 12 people, focused on safety and dosing. It may not show benefit, and there are risks like side effects from radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1 neoplasm neoplastic disease or syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA MULTIFORME NEOPLASTIC DISEASE

Contacts and locations

Locations

Gold Coast University Hospital

Gold Coast, Queensland, 4215, Australia
Institut für Nuklearmedizin und Endokrinologie

Linz, Austria
Olivia Newton John Cancer Research Institute/Austin Health

Melbourne, Victoria, Australia
Royal Adelaide Hospital

Adelaide, South Australia, Australia
UNMC Utrecht

Utrecht, 3051, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.